Tuesday, Eli Lilly and Company (LLY) announced new long-term data from the LUCENT-3 open-label extension study in patients with moderately to severely active ulcerative colitis treated with Omvoh.
The study showed that 63.5 percent of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.
Moreover, the long-term safety profile in patients with moderately to severely active UC was consistent with the known safety profile of Omvoh with no new safety signals observed.
In the pre-market hours, LLY is trading at $966.06, down 0.23 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.